Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 2Head & Neck 2Breast 2Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 13Nasopharyngeal Carcinoma 13Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 4Pancreatic Neoplasms 4Nasopharyngeal Neoplasms 4Melanoma 4Head and Neck Neoplasms 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Mesothelioma 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Bile Duct Neoplasms 2Anus Neoplasms 2Adenocarcinoma Of Esophagus 2

Interventions

pembrolizumab 7Nivolumab 4Carboplatin 4Cisplatin 3spartalizumab 2regorafenib 2durvalumab 2Paclitaxel 2Itraconazole 2Immune Checkpoint Inhibitors 2Gemcitabine 2Fluorouracil 2130-nm albumin-bound paclitaxel 2tremelimumab 1toripalimab 1ribociclib 1osimertinib 1obinutuzumab 1nazartinib 1naptumomab estafenatox 1liposomal doxorubicin 1enzalutamide 1elgemtumab 1aflibercept 1abiraterone 1SGN-LIV1A 1Ritonavir 1Remote Patient Monitoring 1Oxaliplatin 1ON 01910 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × spartalizumab × Head & Neck × Clear all
NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Novartis

Phase 1 Terminated
122 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡